Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Men with PAH had a larger right heart size and worse survival than women, independent of body size and functional status, a ...

After adjusting for sociodemographic factors, those patients still had an 8.02-fold increased risk of SF (OR8.02, 95% CI: 4.47–14.39) and a 15.13-fold increased risk of AF (OR15.13, 95% CI: 7.09–32.3 ...